Abstract
Get full access to this article
View all access options for this article.
References
1.
Sarepta Therapeutics. Sarepta Therapeutics Announces Positive Vote from U.S. FDA Advisory Committee Meeting for SRP-9001 Gene Therapy to Treat Duchenne Muscular Dystrophy. 2023 . Available from: https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-announces-positive-vote-us-fda-advisory [Last accessed:
May 13 , 2023
].
2.Scribe Therapeutics . Scribe Announces Collaboration with Prevail, a Wholly Owned Subsidiary of Lilly, to Accelerate In Vivo CRISPR-based Genetic Medicines for Neurological and Neuromuscular Diseases. May 16, 2023. Available from: https://www.scribetx.com/press-release-scribe-announces-collaboration-with-prevail-a-wholly-owned-subsidiary-of-lilly-to-accelerate-in-vivo-crispr-based-genetic-medicines-for-neurological-and-neuromuscular-diseases/ [Last accessed:
May 16 , 2023
].
3.Massachusetts Workforce Development System (MassHire) . Worker Adjustment and Retraining Act (WARN) weekly report. Week ending May 5, 2023. Available from: https://www.mass.gov/service-details/worker-adjustment-and-retraining-act-warn-weekly-report [Last accessed:
May 12 , 2023
].
4.
Waldron
J.
Takeda confirms fallout from gene therapy R&D refocus: up to 186 layoffs. FierceBiotech 2023. Available from: https://www.fiercebiotech.com/biotech/takeda-confirms-fallout-gene-therapy-rd-refocus-186-redundancies [Last accessed:
May 12 , 2023
].
5.Taysha Gene Therapies . Form 8-K, April 27, 2023. Taysha Gene Therapies, Inc.: Dallas, TX. Available from: https://ir.tayshagtx.com/static-files/b9c68527-cdef-4102-a250-a47c4e4aa9e6 [Last accessed:
May 11 , 2023
].
6.
Philippidis A. Taysha Faces Stock Delisting, Scraps $75M Durham Manufacturing Facility. 2023 . Available from: https://www.genengnews.com/topics/genome-editing/gene-therapy/taysha-faces-stock-delisting-scraps-75m-durham-manufacturing-facility/ [Last accessed:
May 11 , 2023
].
7.Ascend Gene & Cell Therapies . Gene & Cell Therapy Manufacturing Specialist Ascend Launches with Over $130M of Funding as Expert Teams Merge. 2023 . Available from https://static1.squarespace.com/static/61eabe036a52cb117905aca8/t/645ba1bc07ba28045e7e577d/1683726780991/Ascend+press+release.pdf [Last accessed:
May 12 , 2023
].
8.Bluebird Bio. Bluebird bio Submits Biologics License Application (BLA) to FDA for Lovotibeglogene Autotemcel (lovo-cel) for Patients with Sickle Cell Disease (SCD) 12 Years and Older with a History of Vaso-Occlusive Events . 2023 . Available from https://investor.bluebirdbio.com/news-releases/news-release-details/bluebird-bio-submits-biologics-license-application-bla-fda-0 [Last accessed:
May 11 , 2023
].